Stefan GrÃ¤f

List of Publications by Year
in descending order

42 papers	4,197 citations
25 h-index (236925)	42 g-index (265206)
51 all docs	51 docs citations
51 times ranked	5641 citing authors

#	Article	IF	Citations
1	Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Medicine, 2015, 21, 777-785.	30.7	389
2	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care â€" Preliminary Report. New England Journal of Medicine, 2021, 385, 1868-1880.	27.0	352
3	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. American Journal of Human Genetics, 2017, 100, 75-90.	6.2	343
4	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	27.8	338
5	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
6	Federated learning for predicting clinical outcomes in patients with COVID-19. Nature Medicine, 2021, 27, 1735-1743.	30.7	300
7	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
8	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	2.5	185
9	Loss-of-function nuclear factor ΐºB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. Journal of Allergy and Clinical Immunology, 2018, 142, 1285-1296.	2.9	185
10	Molecular genetic framework underlying pulmonary arterial hypertension. Nature Reviews Cardiology, 2020, 17, 85-95.	13.7	181
11	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation, 2017, 135, 460-475.	1.6	154
12	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020, 583, 90-95.	27.8	148
13	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
14	Phenotypic Characterization of *EIF2AK4* Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
15	Genome-wide identification and characterisation of human DNA replication origins by initiation site sequencing (ini-seq). Nucleic Acids Research, 2016, 44, gkw760.	14.5	86
16	Characterization of *GDF2* Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
17	Loss-of-Function *ABCC8* Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	3.6	62
18	Familial pulmonary arterial hypertension by *KDR* heterozygous loss of function. European Respiratory Journal, 2020, 55, 1902165.	6.7	49

#	ARTICLE	IF	CITATIONS
19	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	5.6	45
20	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine, 2021, 13, 80.	8.2	43
21	*NOTCH3* variants are more common than expected in the general population and associated with stroke and vascular dementia: an analysis of 200 000 participants. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 694-701.	1.9	39
22	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	6.2	36
23	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111.	5.6	35
24	The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801805.	6.7	31
25	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. European Respiratory Journal, 2019, 53, 1801429.	6.7	31
26	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	6.7	31
27	Bayesian Inference Associates Rare *KDR* Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
28	How common are single gene mutations as a cause for lacunar stroke?. Neurology, 2019, 93, e2007-e2020.	1.1	26
29	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	6.7	26
30	Biallelic variants of *ATP13A3* cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality. Journal of Medical Genetics, 2022, 59, 906-911.	3.2	22
31	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	12.8	21
32	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	5.6	19
33	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. Chest, 2021, 160, 1442-1458.	0.8	17
34	'There and Back Again'—Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. Genes, 2020, 11, 1408.	2.4	11
35	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 81-93.	5.6	9
36	Eukaryotic life without tQCUG: the role of Elongator-dependent tRNA modifications in Dictyostelium discoideum. Nucleic Acids Research, 2020, 48, 7899-7913.	14.5	5

#	Article	IF	Citations
37	The role of genomics and genetics in pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202013.	0.4	5
38	Response by Hadinnapola et al to Letter Regarding Article, â€œPhenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertensionâ€. Circulation, 2018, 137, 2413-2414.	1.6	3
39	Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension. Genes, 2020, 11, 1247.	2.4	3
40	Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival. Chest, 2022, 161, 1651-1656.	0.8	2
41	Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). Practical Neurology, 2021, 21, 448-451.	1.1	0
42	Biased apelin receptor agonists for cardiovascular disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY85-1.	0.0	0